The aim of this research is to investigate the pulmonary resistance (sPAP/CO) by echocardiography and other hemodynamic outcomes before and after relocation (high altitude near their living altitude vs. sea level) in patients with diagnosed pulmonary arterial hypertension according to guidelines, who permanently live at high altitude over 2600m.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients aged 18-80 years and of all genders
Permanent residence \> 2600 m
Diagnosis of pulmonary arterial hypertension PAH (PAHHA-Group) according to guidelines
Patients are stable on therapy
NYHA (new york heart association) functional class I-III
written informed consent to participate in the study
You may not be if
Age \<18 years or \>80 years
unstable condition
Patients who cannot follow the study investigations
Patient permanently living \< 2600m.
Patients who traveled and stayed overnight at altitudes \<2000 m in the past 4 weeks.
Patients with moderate to severe concomitant lung disease (FEV1\<70% or forced vital capacity \<70%), severe parenchymal lung disease, severe smokers (\>20 cigarettes/day)
Severely hypoxemic patients at 2850m permanently having persistent SpO2 (oxygen saturation by pulseoximetry) \<80% on ambient air.
Patient with a non-corrected ventricular septum defect
Relevant concomitant other disease of the heart, kidney, liver, blood (anemia hemoglobin\<11 g/dl)
Clareo Health | Assessment of Total Pulmonary Resistance sPAP/CO Between High Altitude HA vs. Sea Level LA in Patients With Pulmonary Arterial Hypertension PAH
